50
Participants
Start Date
May 5, 2015
Primary Completion Date
November 5, 2019
Study Completion Date
November 5, 2019
CAVATAK
CAVATAK is a preparation of CVA21
Ipilimumab
Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
Sylvester Comprehensive Cancer Center, Miami
Advocate Health, SC, Park Ridge
Huntsman Cancer Institute, Salt Lake City
The Angeles Clinic & Research Institute, Los Angeles
John Wayne Cancer Institute, Santa Monica
City of Hope National Medical Center,, Duarte
UC San Diego Moores Cancer Center, La Jolla
Providence Portland Medical Center, Portland
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Atlantic Melanoma Center, Morristown
Lead Sponsor
Providence Health & Services
OTHER
Viralytics
INDUSTRY